The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Taiwanese patients with diffuse large B-cell lymphoma: A retrospective analysis in the Tri-Service General Hospital

Jia Hong Chen, Wei Yau Kao, Ping Ying Chang, Ming Shen Dai, Yeu Chin Chen, Tsu Yi Chao, Ching Liang Ho

Research output: Contribution to journalArticle

Abstract

Objective: Diffuse large B-cell lymphoma (DLBCL), as defined by 2008 World Health Organization (WHO) classification, is the most common subtype. Rituximab (R), a chimerical monoclonal antibody against the CD20 B-cell antigen, has shown improved outcomes in patients with newly diagnosed DLBCL. Based on clinical results, a retrospective analysis was performed of treatment outcome, using rituximab, in patients with DLBCL. Materials & Methods: Two hundred and twenty newly diagnosed patients with non-Hodgkin's lymphoma (NHL), between June 2001 and December 2006, were evaluated for histological subtypes and clinical characteristics. Ninety-nine patients with DLBCL were investigated further for clinical results after CHOP-like chemotherapy with or without rituximab. Results: Among 220 patients with NHL, 172 (78.2%) patients had B-cell lineage and 35 (15.9%) T/NK-cell lineage. Ninety-nine patients were diagnosed with DLBCL, which was the most common B-cell lineage subtype and accounted for 45% of the patients with NHL. Among the 99 patients with DLBCL, 43 received R-CHOP like chemotherapy (R-CHOP group), 29 received CHOP-like chemotherapy alone (CHOP group), 13 had other chemotherapy regimens, and 14 received supportive care only. The response rate was significantly higher in the R-CHOP group compared to the CHOP group (86% vs. 58.6%, p=0.012). The progression free survival was significantly higher in the R-CHOP group (p=0.05, HR=0.524, CI, 95%, 0.255-1.075). The survival benefit was also more favorable in the R-CHOP group (p=0.06, HR=0.520, CI, 95%, 0.253-1.067). Conclusions: DLBCL is the most common subtype of NHL. The addition of rituximab to CHOP-like chemotherapy increased the response rate and improved the therapeutic outcome with regard to the progression free survival. A longer follow-up duration is necessary to evaluate overall survival.

Original languageEnglish
Pages (from-to)217-224
Number of pages8
JournalJournal of Medical Sciences (Taiwan)
Volume32
Issue number5
Publication statusPublished - Oct 20 2012
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
General Hospitals
Non-Hodgkin's Lymphoma
Cell Lineage
Drug Therapy
B-Lymphocytes
Therapeutics
Disease-Free Survival
Rituximab
Survival
Natural Killer Cells
Monoclonal Antibodies
Antigens

Keywords

  • CHOP
  • Diffuse large B cell lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Taiwanese patients with diffuse large B-cell lymphoma : A retrospective analysis in the Tri-Service General Hospital. / Chen, Jia Hong; Kao, Wei Yau; Chang, Ping Ying; Dai, Ming Shen; Chen, Yeu Chin; Chao, Tsu Yi; Ho, Ching Liang.

In: Journal of Medical Sciences (Taiwan), Vol. 32, No. 5, 20.10.2012, p. 217-224.

Research output: Contribution to journalArticle

@article{f423d31de062415b81d55f4e053f83b0,
title = "The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Taiwanese patients with diffuse large B-cell lymphoma: A retrospective analysis in the Tri-Service General Hospital",
abstract = "Objective: Diffuse large B-cell lymphoma (DLBCL), as defined by 2008 World Health Organization (WHO) classification, is the most common subtype. Rituximab (R), a chimerical monoclonal antibody against the CD20 B-cell antigen, has shown improved outcomes in patients with newly diagnosed DLBCL. Based on clinical results, a retrospective analysis was performed of treatment outcome, using rituximab, in patients with DLBCL. Materials & Methods: Two hundred and twenty newly diagnosed patients with non-Hodgkin's lymphoma (NHL), between June 2001 and December 2006, were evaluated for histological subtypes and clinical characteristics. Ninety-nine patients with DLBCL were investigated further for clinical results after CHOP-like chemotherapy with or without rituximab. Results: Among 220 patients with NHL, 172 (78.2{\%}) patients had B-cell lineage and 35 (15.9{\%}) T/NK-cell lineage. Ninety-nine patients were diagnosed with DLBCL, which was the most common B-cell lineage subtype and accounted for 45{\%} of the patients with NHL. Among the 99 patients with DLBCL, 43 received R-CHOP like chemotherapy (R-CHOP group), 29 received CHOP-like chemotherapy alone (CHOP group), 13 had other chemotherapy regimens, and 14 received supportive care only. The response rate was significantly higher in the R-CHOP group compared to the CHOP group (86{\%} vs. 58.6{\%}, p=0.012). The progression free survival was significantly higher in the R-CHOP group (p=0.05, HR=0.524, CI, 95{\%}, 0.255-1.075). The survival benefit was also more favorable in the R-CHOP group (p=0.06, HR=0.520, CI, 95{\%}, 0.253-1.067). Conclusions: DLBCL is the most common subtype of NHL. The addition of rituximab to CHOP-like chemotherapy increased the response rate and improved the therapeutic outcome with regard to the progression free survival. A longer follow-up duration is necessary to evaluate overall survival.",
keywords = "CHOP, Diffuse large B cell lymphoma, Rituximab",
author = "Chen, {Jia Hong} and Kao, {Wei Yau} and Chang, {Ping Ying} and Dai, {Ming Shen} and Chen, {Yeu Chin} and Chao, {Tsu Yi} and Ho, {Ching Liang}",
year = "2012",
month = "10",
day = "20",
language = "English",
volume = "32",
pages = "217--224",
journal = "Journal of Medical Sciences",
issn = "1011-4564",
publisher = "國防醫學院",
number = "5",

}

TY - JOUR

T1 - The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Taiwanese patients with diffuse large B-cell lymphoma

T2 - A retrospective analysis in the Tri-Service General Hospital

AU - Chen, Jia Hong

AU - Kao, Wei Yau

AU - Chang, Ping Ying

AU - Dai, Ming Shen

AU - Chen, Yeu Chin

AU - Chao, Tsu Yi

AU - Ho, Ching Liang

PY - 2012/10/20

Y1 - 2012/10/20

N2 - Objective: Diffuse large B-cell lymphoma (DLBCL), as defined by 2008 World Health Organization (WHO) classification, is the most common subtype. Rituximab (R), a chimerical monoclonal antibody against the CD20 B-cell antigen, has shown improved outcomes in patients with newly diagnosed DLBCL. Based on clinical results, a retrospective analysis was performed of treatment outcome, using rituximab, in patients with DLBCL. Materials & Methods: Two hundred and twenty newly diagnosed patients with non-Hodgkin's lymphoma (NHL), between June 2001 and December 2006, were evaluated for histological subtypes and clinical characteristics. Ninety-nine patients with DLBCL were investigated further for clinical results after CHOP-like chemotherapy with or without rituximab. Results: Among 220 patients with NHL, 172 (78.2%) patients had B-cell lineage and 35 (15.9%) T/NK-cell lineage. Ninety-nine patients were diagnosed with DLBCL, which was the most common B-cell lineage subtype and accounted for 45% of the patients with NHL. Among the 99 patients with DLBCL, 43 received R-CHOP like chemotherapy (R-CHOP group), 29 received CHOP-like chemotherapy alone (CHOP group), 13 had other chemotherapy regimens, and 14 received supportive care only. The response rate was significantly higher in the R-CHOP group compared to the CHOP group (86% vs. 58.6%, p=0.012). The progression free survival was significantly higher in the R-CHOP group (p=0.05, HR=0.524, CI, 95%, 0.255-1.075). The survival benefit was also more favorable in the R-CHOP group (p=0.06, HR=0.520, CI, 95%, 0.253-1.067). Conclusions: DLBCL is the most common subtype of NHL. The addition of rituximab to CHOP-like chemotherapy increased the response rate and improved the therapeutic outcome with regard to the progression free survival. A longer follow-up duration is necessary to evaluate overall survival.

AB - Objective: Diffuse large B-cell lymphoma (DLBCL), as defined by 2008 World Health Organization (WHO) classification, is the most common subtype. Rituximab (R), a chimerical monoclonal antibody against the CD20 B-cell antigen, has shown improved outcomes in patients with newly diagnosed DLBCL. Based on clinical results, a retrospective analysis was performed of treatment outcome, using rituximab, in patients with DLBCL. Materials & Methods: Two hundred and twenty newly diagnosed patients with non-Hodgkin's lymphoma (NHL), between June 2001 and December 2006, were evaluated for histological subtypes and clinical characteristics. Ninety-nine patients with DLBCL were investigated further for clinical results after CHOP-like chemotherapy with or without rituximab. Results: Among 220 patients with NHL, 172 (78.2%) patients had B-cell lineage and 35 (15.9%) T/NK-cell lineage. Ninety-nine patients were diagnosed with DLBCL, which was the most common B-cell lineage subtype and accounted for 45% of the patients with NHL. Among the 99 patients with DLBCL, 43 received R-CHOP like chemotherapy (R-CHOP group), 29 received CHOP-like chemotherapy alone (CHOP group), 13 had other chemotherapy regimens, and 14 received supportive care only. The response rate was significantly higher in the R-CHOP group compared to the CHOP group (86% vs. 58.6%, p=0.012). The progression free survival was significantly higher in the R-CHOP group (p=0.05, HR=0.524, CI, 95%, 0.255-1.075). The survival benefit was also more favorable in the R-CHOP group (p=0.06, HR=0.520, CI, 95%, 0.253-1.067). Conclusions: DLBCL is the most common subtype of NHL. The addition of rituximab to CHOP-like chemotherapy increased the response rate and improved the therapeutic outcome with regard to the progression free survival. A longer follow-up duration is necessary to evaluate overall survival.

KW - CHOP

KW - Diffuse large B cell lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84869228192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869228192&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84869228192

VL - 32

SP - 217

EP - 224

JO - Journal of Medical Sciences

JF - Journal of Medical Sciences

SN - 1011-4564

IS - 5

ER -